Portfolio company
Bitterroot Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Bitterroot Bio develops protein therapies to treat atherosclerotic cardiovascular disease for patients by inhibiting specific receptors to reduce vascular inflammation and plaque build-up.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Athernal Bio
The company develops targeted immunotherapies for patients with high-risk clonal haematopoiesis to prevent the development of blood cancers.
Revier Therapeutics
This company develops orally available small molecules targeting class IIa histone deacetylases to treat patients with heart failure and atherosclerotic cardiovascular diseases.
Brano Therapeutics
This company develops small-molecule inhibitors to treat heart failure and metabolic dysfunction for patients with cardiovascular diseases.
Braveheart Bio
This biopharmaceutical company develops small-molecule therapeutics to treat patients with hypertrophic cardiomyopathy and other serious cardiovascular conditions.
Cyclarity
This biopharmaceutical company develops engineered cyclodextrin molecules to remove arterial plaque and treat age-related vascular diseases for patients with atherosclerosis and heart conditions.
Rezera (formerly NodThera)
Rezera develops oral NLRP3 inhibitors to treat patients with cardiovascular and neurologic diseases, specifically focusing on peripheral artery disease and neuroinflammation.
BioAge Labs
This company develops therapeutic drugs targeting the biology of human aging to treat patients with metabolic and cardiovascular diseases.
Serna Bio
This company develops an AI-native platform to discover small molecule drugs targeting RNA for pharmaceutical partners treating respiratory and other complex diseases.